RxDoctor Payments Data

John Monroe, MD

Family Medicine · Goodyear, AZNPI 1346312451

Payments from drug & device makers

$12,126in general payments, 2019–2025

Across 855 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • GSK$985
  • Pfizer$963
  • Abbott$872
  • Boehringer Ingelheim$811
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$12,101100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,126 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$142,177
Medicare patients
515
Services billed
2,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$150,314
OzempicSemaglutide71$95,466
JardianceEmpagliflozin55$79,654
RybelsusSemaglutide36$65,459
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$43,289
TrulicityDulaglutide34$36,767
FarxigaDapagliflozin Propanediol21$35,110
JanuviaSitagliptin Phosphate19$30,047
XareltoRivaroxaban15$24,446
ProliaDenosumab13$23,121
MounjaroTirzepatide15$22,550
MyrbetriqMirabegron19$18,955
Breo ElliptaFluticasone/Vilanterol27$16,154
Repatha SureclickEvolocumab12$12,630
Atrovent HfaIpratropium Bromide27$12,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,667$160,925107 claims
PfizerEliquis$963$150,314119 claims
Boehringer IngelheimJardiance$811$79,65455 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$985$69,25782 claims
Lilly USA, LLCTrulicity, Mounjaro$447$59,31749 claims
AstraZenecaFarxiga, Symbicort$306$40,99534 claims
MerckJanuvia$158$30,04719 claims
Johnson & JohnsonXarelto$139$24,44615 claims
AmgenProlia$380$23,12113 claims
Astellas Pharma US IncMyrbetriq$405$18,95519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →